8,027 reports of this reaction
4.1% of all TIRZEPATIDE reports
#4 most reported adverse reaction
EXTRA DOSE ADMINISTERED is the #4 most commonly reported adverse reaction for TIRZEPATIDE, manufactured by Eli Lilly and Company. There are 8,027 FDA adverse event reports linking TIRZEPATIDE to EXTRA DOSE ADMINISTERED. This represents approximately 4.1% of all 196,029 adverse event reports for this drug.
TIRZEPATIDE has an overall safety score of 78 out of 100. Patients taking TIRZEPATIDE who experience extra dose administered should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EXTRA DOSE ADMINISTERED is moderately reported among TIRZEPATIDE users, representing a notable but not dominant share of adverse events.
In addition to extra dose administered, the following adverse reactions have been reported for TIRZEPATIDE:
The following drugs have also been linked to extra dose administered in FDA adverse event reports:
EXTRA DOSE ADMINISTERED has been reported as an adverse event in 8,027 FDA reports for TIRZEPATIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EXTRA DOSE ADMINISTERED accounts for approximately 4.1% of all adverse event reports for TIRZEPATIDE, making it a notable side effect.
If you experience extra dose administered while taking TIRZEPATIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.